| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
During its 20-plus-year history, MVB Bank has grown from a community bank with 35 employees to a forward-thinking, NASDAQ-listed, Russell 2000® company with more than 400 Team Members living in more than 25 different states. Headquartered in Fairmont, West Virginia, MVB Bank and the Banks subsidiaries, the MVB Community Development Corp., Chartwell Compliance, Paladin and Trabian, provide financial services to individuals and corporate clients in the Mid-Atlantic region and beyond. MVB Financial Corp., the holding company of MVB Bank, is publicly traded on The Nasdaq Capital Market under the ticker "MVBF."
At POCN, we seek to support the careers and clinical practices of NPs and PAs - Advanced Clinicians by partnering with life science companies who recognize their critical role on the front lines of healthcare. We are the largest network of Advanced Clinicians in the U.S. and strive to support and enable success for them at every turn. POCN provides Advanced Clinicians with an opportunity engine to grow their careers, earn valuable financial incentives, and increase their clinical knowledge and practice productivity. Recognizing the vital relationship between NPs, PAs, and the broader healthcare and life sciences industries, POCN specializes in developing peer–validated programs that include engaging live and virtual events, helpful patient education resources, incentivized market research programs, clinical reference and prescribing tools, promoted speaking opportunities, as well as CME and continuous learning modules on a variety of disease states and therapies.
Selena Group is a leading global manufacturer of construction chemicals and polyurethane foam, established in 1992 and based in Wrocław, Poland. The company operates in 18–19 countries with around 1,800–2,000 employees and has 30–35 subsidiaries, including manufacturing facilities in Poland, South Korea, China, Romania, Turkey, Spain, Kazakhstan, and Italy. Selena Group is recognized as one of the top four manufacturers of assembly foam and a significant distributor of construction chemicals. Its product range includes high-yield polyurethane foams, sealants, adhesives, waterproofing systems, and thermal insulation solutions. The company operates through four specialized divisions: Interior & Decorations, Windows & Doors, Waterproofing, and Walls, Facades & Chemical Constructions. Selena serves 100 markets worldwide, focusing on professional contractors, industrial users, and home builders, while emphasizing sustainability and innovation in its offerings.